Topline readout: In an ongoing Phase 1 study of GTA182 in MTAP-deleted solid tumors, the objective response rate was 30.0% among 30 efficacy-evaluable patients treated at active doses, with a disease control rate of 83.3%. In the MTAP-deleted NSCLC subgroup (n=14), the objective response rate reached 57.1% with evidence of intracranial activity in two of three patients with baseline brain metastases. Grade ≥3 treatment-related adverse events occurred in 26.8% of treated patients; the most common treatment-related events were anemia (51.2%), decreased appetite (43.9%), and asthenia (39.0%). Exposure increased dose-proportionally through 450 mg once daily, PRMT5 pathway inhibition was robust with mean plasma SDMA reduction of 71.8% at active doses, and the maximum tolerated dose has not been reached.
Apeiron Therapeutics presented the first clinical data for GTA182, an oral, brain-penetrant, MTA-cooperative PRMT5 inhibitor, at ESMO Asia 2025. As of the October 9, 2025 cutoff, 41 patients with MTAP-deleted advanced solid tumors received 20–450 mg once daily; 30 patients treated within the active-dose range (100–450 mg) were evaluable for efficacy. Responses were seen across dose levels, including within the NSCLC subgroup, aligning pharmacodynamic target engagement with emerging antitumor activity and early signs of CNS penetration.
Strategically, Apeiron is stepping into a crowded synthetic-lethality race where multiple MTA-cooperative PRMT5 and MAT2A programs are vying for the same MTAP-deleted population. The emphasis on brain penetration and a clear NSCLC signal is a deliberate differentiation attempt, positioning GTA182 for cohorts enriched for patients with brain metastases—a clinically and operationally meaningful niche as CNS involvement increasingly shapes first-line NSCLC development. The PK/PD coherence and lack of an MTD at current doses provide room to tune an exposure window that sustains SDMA suppression while managing class-typical hematologic toxicity. The data also suggest a monotherapy foothold that could de-risk future combination strategies, where overlapping myelosuppression has complicated regimen design elsewhere in the class.
Operationally, this program underscores the growing importance of front-loaded biomarker infrastructure. Sites will need reliable, rapid MTAP deletion ascertainment—often via copy-number calls on tissue NGS—with processes to minimize screen failures and turnaround time. Trials that target intracranial endpoints will require standardized CNS imaging workflows and central review, adding complexity but also increasing the clinical relevance of responses in NSCLC. CROs and central labs capable of pre-screening large molecular backlogs will be critical to maintain accrual velocity. For regulators, the path likely runs through early CDx alignment or a pragmatic LDT-bridging strategy, given heterogeneous detection practices for MTAP loss across platforms.
Next, watch for dose selection and expansion cohort architecture. A recommended Phase 2 dose anchored to a plateau in SDMA suppression and tolerability will signal whether Apeiron prioritizes durability over peak response. Confirmation of intracranial activity with predefined CNS response criteria and longer follow-up on response durability will determine how aggressively the company chases a registrational path in MTAP-deleted NSCLC. Competitive timing matters: multiple peer programs are approaching or in expansion with similar biomarker strategies. Key risks include hematologic toxicity as exposure increases, potential variability in MTAP detection affecting eligibility and generalizability, and the need to demonstrate consistency across histologies beyond NSCLC. If the signal holds and CNS responses are reproducible, expect rapid build-out of NSCLC and brain metastasis cohorts, early CDx planning, and a sharpened focus on operational execution to convert a class-consistent mechanism into a clinically and commercially defensible position.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
